SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs antipsychotics: Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term Spontaneous reporting by study participants
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG Specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight gain · patients with schizophrenia SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight… compared with ANY ANTIPSYCHOTIC DRUG (low certainty). Sulpiride augmentation for schizophrenia (2010) · Cochrane Headline outcomes only | RR 0.3 [0.09, 0.99] | 1 study · 64 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Sulpiride augmentation for schizophrenia 2010 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.